MYERS ROBERT L
Known title: Chief Financial OfficerCIK: 0001553600
MYERS ROBERT L's purchase track record
MYERS ROBERT L has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/2/2022 | AGPU | $5K | -20.4% | -67.6% | +5.2% |
| 5/20/2022 | AGPU | $5K | +54.1% | +11.1% | +1.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AGPU | ▼ Sell | Tax Withholding | 510 | $2K | 9/25/2023 | View on chart |
| AGPU | ▲ Buy | Option Exercise | 1,667 | — | 9/25/2023 | View on chart |
| AGPU | ▲ Buy | Open Market | 8,795 | $5K | 12/2/2022 | View on chart |
| AGPU | ▲ Buy | Option Exercise | 33,333 | — | 9/23/2022 | View on chart |
| AGPU | ▼ Sell | Tax Withholding | 10,199 | $4K | 9/23/2022 | View on chart |
| AGPU | ▲ Buy | Open Market | 16,125 | $5K | 5/20/2022 | View on chart |
| AGPU | ▲ Buy | Option Exercise | 33,334 | $38K | 9/23/2021 | View on chart |
| AGPU | ▼ Sell | Other | 10,200 | $12K | 9/23/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Axe Compute Signs $266M in AI Contracts, Exits Cancer Business
Axe Compute has secured over $266 million in new AI infrastructure contracts since mid-August. The company is also selling its cancer business to fully transition into an AI-focused entity. These moves mark a significant strategic shift for the stock, which trades with high beta and has a wide 52-week range.
Axe Compute Signs $266M in AI Contracts, Exits Cancer Business. Axe Compute has secured over $266 million in new AI infrastructure contracts since mid-August. The company is also selling its cancer business to fully transition into an AI-focused entity. These moves mark a significant strategic shift for the stock, which trades with high beta and has a wide 52-week range.